Welcome to our dedicated page for Telomir Pharms SEC filings (Ticker: TELO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sorting through Telomir Pharmaceuticals’ dense R&D disclosures can feel like a lab manual disguised as a financial report. Whether you’re hunting for Telomir Pharmaceuticals insider trading Form 4 transactions before pivotal announcements or trying to confirm cash runway in the latest Telomir Pharmaceuticals quarterly earnings report 10-Q filing, the raw EDGAR pages rarely cooperate. Stock Titan captures every submission as it posts, then layers AI that translates biotech jargon into plain English.
Need Telomir Pharmaceuticals Form 4 insider transactions real-time? One click delivers them. Our platform highlights what matters: real-time alerts, side-by-side burn-rate trends, and pop-up definitions so Telomir Pharmaceuticals SEC filings explained simply is reality. Ask, “What did the CFO buy last quarter?” and receive concise narratives, charts and context drawn from Telomir Pharmaceuticals earnings report filing analysis. The AI also links Telomir-1 milestones to potential 8-K triggers, giving you continuous context.
Because Telomir’s value rests on future breakthroughs, investors scrutinize forward-looking risk factors and dilution details. Our tools make understanding Telomir Pharmaceuticals SEC documents with AI effortless: see Telomir Pharmaceuticals executive stock transactions Form 4 mapped against financing rounds, a Telomir Pharmaceuticals annual report 10-K simplified into key bullet points, and the newest Telomir Pharmaceuticals proxy statement executive compensation parsed into comparable tables. When developments emerge, find Telomir Pharmaceuticals 8-K material events explained alongside peer benchmarks—updated the moment they post.
Telomir Pharmaceuticals (NASDAQ: TELO) reported new preclinical findings showing that its small molecule Telomir-1 reduced survival of aggressive human pancreatic cancer (PANC-1) cells in vitro. The compound produced a concentration-dependent decrease in cell viability and mitochondrial activity, aligning with prior results in triple‑negative breast and prostate cancer models.
The response in pancreatic cells was partially reversed by iron re‑addition, indicating iron‑dependent processes contribute to the effect, while incomplete rescue suggests additional metabolic or epigenetic mechanisms. Telomir-1 has been associated with tumor suppressor genes and iron‑dependent histone demethylases relevant to pancreatic cancer, including MASPIN (SERPINB5), RASSF1A, STAT1, KDM2B, and KDM6B. The company noted pancreatic cancer’s five‑year survival rate is about 12 percent. Telomir plans to expand preclinical research to additional models, including leukemia, and to initiate in vivo validation studies as part of ongoing IND preparation.
John Paul DeJoria, both personally and as trustee of the John Paul DeJoria Family Trust, reports beneficial ownership of 1,774,900 shares of Telomir Pharmaceuticals, Inc. common stock, representing 5.50% of the outstanding class. The filing indicates Mr. DeJoria has sole voting and dispositive power over these shares and states the shares were not acquired to change or influence control of the company. The filing lists the issuer's principal office in Miami, FL, and provides a business address for the reporting person in Georgetown, TX. A power of attorney is attached as an exhibit.
FAQ
What is the current stock price of Telomir Pharms (TELO)?
What is the market cap of Telomir Pharms (TELO)?
